健民药业集团股份有限公司2025 年半年度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2025 年半年度报告 1 / 152 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人汪俊、主管会计工作负责人程朝阳及会计机构负责人（会计主管人员）张英声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 健民药业集团股份有限公司2025 年半年度报告 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在 ...

安徽华塑股份有限公司2025 年半年度报告 公司代码：600935 公司简称：华塑股份 安徽华塑股份有限公司 2025 年半年度报告 1 / 173 安徽华塑股份有限公司2025 年半年度报告 重要提示 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及未来计划、发展战略等前瞻性陈述，不构成对投资者的实质承诺，敬请投资 者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人路明、主管会计工作负责人毕刚及会计机构负责人（会计主管人员）来杰声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细 ...

证券代码：300225 证券简称：*ST金泰 公告编号：2025-084 上海金力泰化工股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 2、预计的业绩： □扭亏为盈 □同向上升 √同向下降 | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：700.00万元–1,000.00万元 | 盈利：1,299.45万元 | | | 比上年同期下降：23% –46% | | | 归属于上市公司股东的扣除非经 常性损益后的净利润 | 盈利：400.00万元–600.00万元 | 盈利：1,179.52万元 | | | 比上年同期下降：49% –66% | | 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据未经会计师审计。 三、业绩变动原因说明 报告期内，公司与战略备库供应商终止合作，导致本期计提其他应收款坏账 准备较上年同期增加700万元；为提高公司 ...

厦门吉比特网络技术股份有限公司 2025 年半年度报告 公司代码：603444 公司简称：吉比特 厦门吉比特网络技术股份有限公司 2025 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 四、公司负责人卢竑岩、主管会计工作负责人林佳金及会计机构负责人（会计主管人员）陈华梁 声明：保证半年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司以未来实施2025年半年度利润分配方案时股权登记日的总股本扣除公司回购专户中已回 购股份后的股本为基数，向全体股东每10股派发现金红利66.00元（含税），合计派发现金红利预 计为4.74亿元（含税），占2025年上半年归属于上市公司股东净利润的73.46%。本次利润分配不进 行资本公积转增股本，不进行其他形式利润分配。 公司自2017年1月上市以来现金分红累计金额为64.89亿元（包含本次已公布但尚未实施的2025 半年度分 ...

福耀玻璃工业集团股份有限公司2025 年半年度报告 一、 本公司董事局、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事局会议。 三、 本半年度报告未经审计。 公司代码：600660 公司简称：福耀玻璃 福耀玻璃工业集团股份有限公司 2025 年半年度报告 1 / 136 福耀玻璃工业集团股份有限公司2025 年半年度报告 重要提示 四、 公司负责人曹德旺、主管会计工作负责人陈向明及会计机构负责人（会计主管人员）丘永 年声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事局决议通过的本报告期利润分配预案或公积金转增股本预案 2025 年上半年本公司按中国企业会计准则编制的合并财务报表中归属于母公司普通股股东 的净利润为人民币 4,804,711,711 元，按国际财务报告准则编制的合并财务报表中归属于母公司 普通股股东的净利润为人民币 4,804,424,175 元。 2025 年 上 半 年 本 公 司 按 中 国 企 业 会 计 准 则 编 制 的 母 公 司 报 表 的 ...

[Definitions](index=4&type=section&id=Section%201%20Definitions) [Company Profile and Key Financial Indicators](index=4&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Information](index=4&type=section&id=I.%20Company%20Information) This section provides basic information about Henan Lingrui Pharmaceutical Co, Ltd, including its name, legal representative, contact details, and stock information - The company's basic information includes its name, legal representative, address, and stock code (600285.SH)[13](index=13&type=chunk)[14](index=14&type=chunk)[19](index=19&type=chunk) [Key Accounting Data and Financial Indicators](index=5&type=section&id=VII.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved steady performance growth, with notable increases in revenue, net profit, and operating cash flow during the reporting period Key Accounting Data | Key Accounting Data | Current Period (Jan-Jun) | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 2,099,205,515.81 RMB | 1,906,007,173.30 RMB | 10.14% | | **Net Profit Attributable to Shareholders** | 474,385,806.53 RMB | 413,032,842.54 RMB | 14.85% | | **Net Profit Attributable to Shareholders (Excluding Non-recurring Items)** | 442,499,140.75 RMB | 394,092,027.35 RMB | 12.28% | | **Net Cash Flow from Operating Activities** | 355,587,506.75 RMB | 290,599,216.93 RMB | 22.36% | | **Total Assets (Period-end)** | 5,572,227,469.60 RMB | 5,016,843,207.73 RMB | 11.07% | Key Financial Indicators | Key Financial Indicators | Current Period (Jan-Jun) | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Basic Earnings Per Share (RMB/Share)** | 0.836 | 0.732 | 14.21% | | **Diluted Earnings Per Share (RMB/Share)** | 0.834 | 0.728 | 14.56% | | **Weighted Average Return on Equity (%)** | 14.65% | 13.89% | Increase of 0.76 ppt | [Non-recurring Profit and Loss Items and Amounts](index=6&type=section&id=IX.%20Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring profit and loss totaled RMB 31.89 million, primarily from investment gains, government grants, and asset disposals - Non-recurring profit and loss for the period totaled **RMB 31.89 million**, mainly from entrusted investment gains, government grants, and asset disposals[24](index=24&type=chunk) [Management Discussion and Analysis](index=7&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) [Industry and Core Business](index=7&type=section&id=I.%20Industry%20and%20Core%20Business%20during%20the%20Reporting%20Period) The company operates in the pharmaceutical manufacturing industry, focusing on health consumer goods and prescription drugs for chronic diseases - The company operates in the pharmaceutical manufacturing sector, focusing on two main areas: **health consumer goods** (orthopedics, pediatrics) and **prescription drugs** (cardiovascular, allergic rhinitis)[27](index=27&type=chunk)[28](index=28&type=chunk)[29](index=29&type=chunk) - The company possesses a diverse product portfolio, including exclusive products like Tongluo Qutong Plaster and Peiyuan Tongnao Capsules, and market-leading products like the "Two Tigers" series[29](index=29&type=chunk)[33](index=33&type=chunk) [Discussion and Analysis of Operations](index=12&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) The company achieved steady growth in H1 2025, driven by innovation, digital transformation, and the successful acquisition of Yingu Pharmaceutical - The company strengthened R&D innovation through internal efforts and collaborations, with its Class 1 innovative drug, Benhuanquinium Bromide Nasal Spray, receiving approval for a new indication for the common cold[38](index=38&type=chunk) - The company advanced intelligent manufacturing and digital transformation, enhancing operational efficiency through production line upgrades, smart warehousing, and integrated information systems[40](index=40&type=chunk)[41](index=41&type=chunk) - The company completed the acquisition of a **90% stake in Yingu Pharmaceutical**, establishing a second growth curve; Yingu contributed **RMB 98.78 million in revenue** and **RMB 13.23 million in net profit** during the period[44](index=44&type=chunk) [Core Competitiveness Analysis](index=14&type=section&id=III.%20Core%20Competitiveness%20Analysis%20during%20the%20Reporting%20Period) The company's core competitiveness is built on its advantages in products, branding, marketing, and intelligent manufacturing - **Product Advantage**: The company has over 100 products in more than ten dosage forms, with exclusive national medical insurance products like Tongluo Qutong Plaster and Peiyuan Tongnao Capsules holding leading market positions[45](index=45&type=chunk) - **Brand Advantage**: The company employs a "1+N" brand strategy, with the core "Lingrui®" brand supported by sub-brands like "Two Tigers®" and "Little Antelope®" to enhance brand influence[46](index=46&type=chunk)[47](index=47&type=chunk) - **Marketing Advantage**: A nationwide marketing network covers OTC, primary care, and clinical channels, enhanced by a developing digital marketing system to improve channel efficiency[47](index=47&type=chunk) - **Intelligent Manufacturing Advantage**: The company leads with the integration of intelligence and industrialization, achieving full-process automated control and earning national recognition as a "Smart Manufacturing Demonstration Factory"[48](index=48&type=chunk) [Analysis of Key Operations](index=15&type=section&id=IV.%20Key%20Operations%20during%20the%20Reporting%20Period) Operating expenses increased significantly due to market expansion and R&D investment, while the acquisition of Yingu Pharmaceutical impacted the balance sheet [Analysis of Changes in Financial Statement Items](index=15&type=section&id=1.%20Analysis%20of%20Changes%20in%20Financial%20Statement%20Items) Selling, general & administrative, and R&D expenses all saw double-digit growth, reflecting increased investment in market expansion, integration, and innovation Changes in Key Financial Statement Items | Item | Current Period Amount (RMB) | Prior Year Period Amount (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | **Selling Expenses** | 994,497,354.35 | 854,905,590.92 | 16.33% | | **General & Administrative Expenses** | 106,577,838.90 | 83,629,248.98 | 27.44% | | **R&D Expenses** | 63,060,862.63 | 47,189,927.33 | 33.63% | | **Net Cash Flow from Investing Activities** | -928,658,991.26 | -609,063,902.67 | N/A | [Analysis of Assets and Liabilities](index=16&type=section&id=1.%20Assets%20and%20Liabilities) Total assets grew 11.07%, driven by the acquisition of Yingu Pharmaceutical, which increased goodwill and intangible assets while decreasing cash reserves - **Cash and cash equivalents** at period-end were **RMB 532 million**, a **decrease of 56.66%** from the beginning of the period, primarily due to the payment for the acquisition of Yingu Pharmaceutical[52](index=52&type=chunk) - **Goodwill** at period-end was **RMB 482 million**, generated from the acquisition of Yingu Pharmaceutical during the period[52](index=52&type=chunk) - **Short-term borrowings** at period-end were **RMB 457 million**, a significant **increase of 1272.41%** from the beginning of the period, mainly due to an increase in discounted notes payable[52](index=52&type=chunk) [Investment Analysis](index=17&type=section&id=1.%20Overall%20Analysis%20of%20External%20Equity%20Investments) The company's primary investment was the acquisition of a 90% stake in Yingu Pharmaceutical for RMB 703.91 million using its own funds - During the reporting period, the company acquired a **90% equity stake in Yingu Pharmaceutical for RMB 704 million** in a major equity investment that has been completed[56](index=56&type=chunk)[58](index=58&type=chunk) - The company participated as a limited partner in two private equity funds, subscribing to Zhuhai Jinyiming Equity Investment Fund (RMB 100 million contributed) and Xiamen Jinyixing Equity Investment Fund (RMB 50 million contributed)[60](index=60&type=chunk) [Risk Analysis](index=21&type=section&id=(I)%20Potential%20Risks) The company faces risks from policy changes, quality control, raw material price volatility, and the inherent uncertainties of R&D - **Policy Risks**: Ongoing healthcare reforms, including centralized procurement and medical insurance payment reforms, pose higher requirements for the company's business model and management[66](index=66&type=chunk) - **Raw Material Price Fluctuation Risk**: The prices of traditional Chinese medicinal materials are subject to factors like industrial policies, natural conditions, and market supply and demand, which could impact operating costs[67](index=67&type=chunk) - **R&D and Innovation Risk**: New drug development is characterized by high investment, high risk, and long cycles, and is subject to uncertainties in technology, approval, and policy[67](index=67&type=chunk) [Corporate Governance, Environment, and Society](index=23&type=section&id=Section%204%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) [Changes in Directors, Supervisors, and Senior Management](index=23&type=section&id=I.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) Mr Wu Xizhen stepped down as Deputy General Manager due to a work arrangement but remains a director and a member of the nomination committee - Due to a work arrangement, **Mr Wu Xizhen resigned from the position of Deputy General Manager** but will continue to serve in his roles on the Board of Directors[71](index=71&type=chunk) [Equity Incentive and Employee Stock Ownership Plans](index=23&type=section&id=III.%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures%20and%20Their%20Impact) The company launched new restricted stock and employee stock ownership plans in 2024, while the 2021 plan was completed and terminated - **2024 Restricted Stock Incentive Plan**: **1.25 million shares were granted to 9 participants**, with the grant registration completed in January 2025[74](index=74&type=chunk)[75](index=75&type=chunk) - **2024 Employee Stock Ownership Plan**: **189 employees participated**, subscribing to **1,956,325 shares**, with the transfer completed in January 2025[76](index=76&type=chunk) - **2021 Employee Stock Ownership Plan**: All shares held under this plan have been sold, and the plan has been terminated[76](index=76&type=chunk) [Significant Matters](index=25&type=section&id=Section%205%20Significant%20Matters) [Material Related-Party Transactions](index=26&type=section&id=X.%20Material%20Related-Party%20Transactions) The company's related-party purchases in the first half of the year amounted to RMB 5.75 million, against an annual forecast of RMB 22.5 million Related-Party Transactions (H1 2025) | Transaction Type | Related Party | Amount (RMB) | | :--- | :--- | :--- | | Purchase of Goods | Henan Lvda Camellia Oil Co, Ltd | 3,702,600 | | Purchase of Goods | Xinyang Daqi Tea Co, Ltd | 506,700 | | Purchase of Goods | Beijing Lingrui Health Materials Co, Ltd | 1,543,700 | [Share Capital Changes and Shareholder Information](index=29&type=section&id=Section%206%20Share%20Capital%20Changes%20and%20Shareholder%20Information) [Changes in Share Capital](index=29&type=section&id=I.%20Changes%20in%20Share%20Capital) Total share capital remained unchanged, but the implementation of a new equity incentive plan increased the number of restricted shares by 1.25 million - Due to the implementation of an equity incentive plan, the company **added 1.25 million restricted shares**, while the total share capital remained unchanged[87](index=87&type=chunk)[88](index=88&type=chunk) [Shareholder Information](index=30&type=section&id=(II)%20Top%20Ten%20Shareholders%20and%20Top%20Ten%20Holders%20of%20Unrestricted%20Shares%20at%20the%20End%20of%20the%20Reporting%20Period) The company had 33,843 shareholders, with Henan Lingrui Group Co, Ltd as the largest shareholder and a diversified institutional investor base - As of the end of the reporting period, the total number of shareholders was **33,843**[92](index=92&type=chunk) Top 5 Shareholders | Shareholder Name | Shares Held at Period-end | Ownership (%) | | :--- | :--- | :--- | | Henan Lingrui Group Co, Ltd | 121,817,898 | 21.48 | | New China Life Insurance Co, Ltd - Traditional - General Insurance Product | 10,169,577 | 1.79 | | Hong Kong Securities Clearing Company Ltd | 9,828,567 | 1.73 | | Qianhai Kaiyuan Shanghai-Hong Kong-Shenzhen Advantage Selected Flexible Allocation Mixed Fund | 8,692,190 | 1.53 | | Basic Pension Insurance Fund Portfolio 15022 | 8,680,484 | 1.53 | [Bond-related Matters](index=33&type=section&id=Section%207%20Bond-related%20Matters) [Corporate Bonds](index=33&type=section&id=I.%20Corporate%20Bonds%20(including%20Enterprise%20Bonds)%20and%20Non-financial%20Enterprise%20Debt%20Financing%20Instruments) The company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible bonds - The company has **no outstanding corporate bonds**, enterprise bonds, non-financial enterprise debt financing instruments, or convertible bonds[102](index=102&type=chunk) [Financial Report](index=34&type=section&id=Section%208%20Financial%20Report) [Financial Statements](index=34&type=section&id=II.%20Financial%20Statements) This section presents the unaudited consolidated and parent company financial statements for the first half of 2025 [Company Profile and Basis of Financial Statement Preparation](index=54&type=section&id=III.%20Company%20Profile) The financial statements are prepared on a going concern basis, with the RMB as the functional currency and a calendar year-end - The company was established through the restructuring of Henan Lingrui Pharmaceutical Co, Ltd and was listed on the Shanghai Stock Exchange on October 18, 2000; the ultimate controlling person is Mr Xiong Wei[136](index=136&type=chunk) - The financial statements are prepared on a **going concern basis**, with no significant uncertainties identified regarding the company's ability to continue as a going concern[137](index=137&type=chunk)[138](index=138&type=chunk) [Significant Accounting Policies and Estimates](index=54&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section outlines the key accounting policies and estimates used, covering areas such as revenue recognition, financial instruments, and R&D expenses - Financial instruments are classified into three categories based on business models and cash flow characteristics, with an **expected credit loss model** applied for impairment[169](index=169&type=chunk)[184](index=184&type=chunk) - **Revenue is recognized** when the customer obtains control of the related goods or services, in accordance with the new revenue standards[262](index=262&type=chunk) - **R&D expenditures** are distinguished between research and development phases, with development-phase expenses capitalized as intangible assets if criteria are met[240](index=240&type=chunk)[241](index=241&type=chunk) [Notes to Consolidated Financial Statement Items](index=89&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed breakdowns and explanations for major items on the consolidated financial statements, including assets, liabilities, and equity - **Cash and cash equivalents** at period-end were **RMB 532 million**, a **decrease of 56.66%** from the beginning of the period, mainly due to the payment for the acquisition of Yingu Pharmaceutical[52](index=52&type=chunk)[290](index=290&type=chunk) - The carrying amount of **accounts receivable** at period-end was **RMB 523 million**, with an allowance for doubtful accounts of RMB 29.79 million, primarily aged within one year[299](index=299&type=chunk)[302](index=302&type=chunk) - The original value of **goodwill** was **RMB 490 million**, of which **RMB 482 million** was generated from the acquisition of Yingu Pharmaceutical during the current period[370](index=370&type=chunk) [Changes in the Scope of Consolidation](index=141&type=section&id=IX.%20Changes%20in%20the%20Scope%20of%20Consolidation) The scope of consolidation changed due to the acquisition of a 90% stake in Yingu Pharmaceutical and the deregistration of a subsidiary - A business combination not under common control occurred, with the company acquiring a **90% equity stake in Yingu Pharmaceutical for RMB 703.91 million in cash** on the acquisition date of February 18, 2025[471](index=471&type=chunk)[472](index=472&type=chunk) - The acquisition of Yingu Pharmaceutical resulted in the recognition of **goodwill amounting to RMB 482.02 million**[472](index=472&type=chunk) - The subsidiary "Xinyang Lingrui Good Taste Co, Ltd" was deregistered during the reporting period[478](index=478&type=chunk)[479](index=479&type=chunk)

公司代码：603171 公司简称：税友股份 四、公司负责人张镇潮、主管会计工作负责人杨培丽及会计机构负责人（会计主管人 员）杨培丽声明：保证半年度报告中财务报告的真实、准确、完整。 税友软件集团股份有限公司 2025 年半年度报告 税友软件集团股份有限公司2025 年半年度报告 1 / 214 税友软件集团股份有限公司2025 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实 性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 二、公司全体董事出席董事会会议。 三、本半年度报告未经审计。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司本报告期不派发现金红利，不送红股，不以公积金转增股本。 六、前瞻性陈述的风险声明 √适用 □不适用 九、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整 性 否 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投资者注意投资风险。 七、是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、是否存在违反规定决策程 ...

深圳市深粮控股股份有限公司 2025 年半年度报告 【2025 年 8 月】 1 深圳市深粮控股股份有限公司 2025 年半年度报告全文 深圳市深粮控股股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王志楷、主管会计工作负责人卢雨禾及会计机构负责人(会计 主管人员)卢成君声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺。《证券时报》《中国证券报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）为本公司选定的信息披露媒体，本公司所有信息均以 在上述选定媒体刊登的信息为准，敬请投资者注意投资风险。 公司已在本报告中详细描述可能存在的相关风险及应对措施，敬请查阅第 三节"管理层讨论与分析"中"公司面临的风险和应对措施"的有关内容。 本报告分别以中、英文编制，在对中外文文本的理解上发生歧义时， ...

惠州中京电子科技股份有限公司 2025 年半年度报告全文 惠州中京电子科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 惠州中京电子科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人 员外的其他董事、监事、高级管理人员均保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律 责任。 董事、监事、高级管理人员异议声明 不适用 公司负责人杨林、主管会计工作负责人文真及会计机构负责人(会计主管 人员)甄炯声声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展规划及事项的陈述，属于计划性事项，不构成 公司对投资者的实质承诺，请投资者注意投资风险。 公司近期不存在可能对公司生产经营状况、财务状况和持续盈利能力有 严重不利影响需作特别提示的风险因素。公司可能面临的风险详见本报告 "第三节管理层讨论与分析"之"十、公司面临的风险和应对措施"，敬请 投资者予以关注。 公司计划不派发现金红利，不送红股，不以 ...

深圳市大族数控科技股份有限公司 2025 年半年度报告全文 深圳市大族数控科技股份有限公司 2025 年半年度报告 2025 年 8 月 1 深圳市大族数控科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人杨朝辉、主管会计工作负责人周小东及会计机构负责人(会计 主管人员)王锋声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异，敬请投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"之"第十条 公司面临的风险 和应对措施"中描述了公司可能面对的风险，敬请广大投资者注意查阅。 备查文件目录 一、法定代表人、主管会计工作的公司负责人、公司会计机构负责人签名并盖章的会计报表原件； 二、报告期内在中国证监会指定网站上公开 ...